Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 3/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | CCKAR | P32238 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4505291 | 0.90 | KMT2A (0.53) | TSHRKMT2AMEN1POLBKDM4E | |
| SCHEMBL4497510 | 0.84 | TSHR (0.74) | TSHRKMT2AMEN1ALDH1A1HPGD | |
| SCHEMBL9501938 | 0.75 | KMT2A (0.54) | TSHRKMT2AMEN1KDM4EALDH1A1 | |
| SCHEMBL7232221 | 0.73 | ALDH1A1 (0.61) | POLBKDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL7232214 | 0.73 | ALDH1A1 (0.61) | POLBKDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL5471030 | 0.70 | ALDH1A1 (0.52) | KMT2AMEN1POLBALDH1A1MAPT | |
| SCHEMBL7869937 | 0.70 | KMT2A (0.65) | TSHRKMT2AMEN1KDM4EALDH1A1 | |
| SCHEMBL8918097 | 0.69 | HTR1F (0.50) | TSHRKMT2AMEN1KDM4EALDH1A1 | |
| SCHEMBL8889074 | 0.66 | KMT2A (0.80) | TSHRKMT2AMEN1KDM4EALDH1A1 | |
| SCHEMBL3455477 | 0.66 | SMN1; SMN2 (0.64) | KMT2APOLBKDM4EALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090137549-A1 | Novel compounds useful for the treatment of degenerative & inflamatory diseases | GALAPAGOS NV (BE) | 2009-05-28 | — | — | US | disclosed |
| WO-2008055959-A1 | NOVEL COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE & INFLAMMATORY DISEASES | GALAPAGOS N.V. (BE) | 2008-05-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137549-A1 | Novel compounds useful for the treatment of degenerative & inflamatory diseases | PDE4A, PDE7B, PDE4B | TSHR 4657/4885KMT2A 3190/4885MEN1 4013/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.